Fig. 6.

Clinical relevance of TAZ and Resistin in TNBC patient adipocytes. (A and B) Representative images showing TAZ (A) or Resistin (B) expression in TNBC patient adipocytes from different clinical stages (Left). The expression was assessed (Right). (Scale bar, 1 mm and 50 μm, n = 149.) (C) Immunohistochemistry staining of Ki67 was performed on TNBC specimens; representative images of periadipocyte areas, periphery areas, and interior areas were shown. (Scale bar, 1 mm [Left] and 50 μm [Right].) (D) Representative images showing Ki67 staining of breast tumor cells in periadipocyte areas from different clinical stages (Left). Ki67+ cells in periadipocyte areas were quantified (Right). (Scale bar, 1 mm and 50 μm, n = 112.) (E) The expression of TAZ or Resistin was categorized by low and high expression as described in Materials and Methods, and the correlation of TAZ with Resistin was analyzed. (F and G) Scatterplots of periadipocyte Ki67+ proportion related to TAZ (F) or Resistin (G) immunohistochemistry scores in patient samples (n = 112). (H) Disease-free survival related to low or high adipocytic TAZ expression was analyzed in 149 breast cancer patients. Data shown are mean ± SEM. Data were analyzed using one-way ANOVA (A, B, and C), Pearson’s correlation (E, F, and G), and log-rank test (H). **P < 0.01, ***P < 0.001.